Sputum-guided Treatment With Comprehensive Care Management in COPD - A Randomized-controlled Trial

NARecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

May 27, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

August 31, 2025

Conditions
COPD
Interventions
COMBINATION_PRODUCT

Sputum-guided management and comprehensive care management

Those in the intervention group will have their treatment determined by the presence and type of airway inflammation whether during AECOPD or as part of clinic optimization. Corticosteroids are given for airway eosinophilia (sputum eosinophils \>3%), and antibiotics for airway neutrophilia (sputum neutrophils ≥65% and total cells \>10 million cells/gram) or a positive sputum culture. Specialized stains to identify aspiration (Oil Red O; (3)) and left ventricular dysfunction (Perl's Prussian blue; (4)) will guide swallowing assessment and cardiac work-up, respectively. If a sputum sample is not produced as an outpatient spontaneously, then sputum induction will be pursued 8 weeks after discharge. If there are no sputum samples to guide inhaler regimen, then it will be determined by the study physician guided by the Canadian Thoracic Society guidelines (2) if a sputum-guided regimen has not already been established.

OTHER

Usual Care

As per previous, this group will receive three follow-up visits with study pulmonologist and clinic personnel interventions.

Trial Locations (2)

L8L 2X2

NOT_YET_RECRUITING

Hamilton General Hospital, Hamilton

L8N 4A6

RECRUITING

St. Joseph's Healthcare Hamilton, Hamilton

All Listed Sponsors
collaborator

Hamilton Academic Health Sciences Organization

OTHER

collaborator

St. Joseph's Healthcare Hamilton

OTHER

collaborator

Hamilton Health Sciences Corporation

OTHER

lead

McMaster University

OTHER